Lexicon Pharmaceuticals Inc (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

LXRX News and Commentary

Caps

How do you think LXRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

260 Outperform
47 Underperform
 

All-Star Players

45 Outperform
11 Underperform
 

Wall Street

5 Outperform
1 Underperform
 

Top LXRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.84)
Submitted February 03, 2014

Lexicon stock is declining but I think it's mostly a tidal effects related to a market correction and weakness in speculative sectors like s,mall cap biopharma. I've made my issues with Lexicon's valuation clear and the street as responded over and… More

Brosan (< 20)
Submitted January 28, 2011

With more less than 80c per share available in cash, LXRX will have a very hard time to keep their heads above water. The me-too compound, LX4211, seems to be stuck in the ground due to the lack of interest in the pharma community. Even it finds a… More

LXRX VS S&P 500 (SPY)

Fools bullish on LXRX are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about LXRX.

Recs

0
Member Avatar NHWeston102 (65.05) Submitted: 4/1/2016 9:28:44 AM : Outperform Start Price: $11.96 LXRX Score: -45.61

A variety of breakthrough drugs which will likely clear FDA this year.

Recs

0
Member Avatar mdriver78 (64.96) Submitted: 3/31/2016 9:35:38 PM : Outperform Start Price: $10.82 LXRX Score: -11.31

The company has two late-phase clinical programs, one of which is for diabetes and the other for a form of cancer.

The company's scientists discovered, after studying diabetes that mice lacking a gene for SGLT1 and SGLT2 (sodium-glucose cotransporter types 1 and 2) showed strong natural anti-diabetic tendencies.

SGLT proteins perform a vital role in transporting glucose and galactose in both the gastrointestinal tract and the kidneys. In the GI tract, they help the body absorb sugars during digestion. In the kidneys, they help the organ prevent excretion of sugars by reabsorbing 90% of what the organ filters.

sotagliflozin, has shown a great deal of promise in treating diabetics. It works by inhibiting the action of the two SGLT proteins, thereby reducing glucose absorption into the blood through the digestive system while increasing glucose excretion through the kidneys.

To date, the drug has been studied in over 600 Type 1 and Type 2 patients, so the company has amassed a large amount of data. In Phase 2 trials, this orally available drug greatly reduced the need for fast-acting insulin in Type 1 patients at mealtimes. After a month of taking the drug, these patients also saw a sharp drop in blood sugar levels, as well as better glycemic control. They also lost almost 2% of their body weight during the trial. Obesity is a significant aggravating factor for diabetes.

Sotagliflozin has huge blockbuster potential for Lexicon in both Type 1 and Type 2 diabetes. The company has signed a partnership deal with Sanofi potentially worth $1.7 billion overall, and the company has already received $300 million upfront. Plus, the company is in line to receive royalties ranging from the low double digits to 40% of sales.

Sotagliflozin is currently in Phase 3 trials, and the first results — in patients with Type 1 disease — are expected from two Phase 3 trials in the second half of this year. The key endpoint for these trials is reduced average blood glucose. Furthermore, Type 2 diabetes trials — a much larger market — are expected to launch by the end of this year.

That's not all, one type of cancer called carcinoid syndrome.

Carcinoid tumors originate from cells of the neuroendocrine system. As they develop, they produce serotonin neurotransmitters and kallikrein enzymes far in excess of what the body can handle. This causes cramps, nausea, vomiting, respiratory problems, flushed skin, thickening of blood vessels and fibrosis in the heart and other parts of the body. But the most common problem carcinoid tumors cause is diarrhea.

Telotristat etiprate works by inhibiting an enzyme that triggers production of serotonin in cancer cells. Last year, LXRX shares rocketed on Phase 3 clinical data for this drug. In August, the company was able to report a significant reduction in bowel movements. With the patients taking a 250 mg dose, there was a 29% reduction. At 500 mg, the reduction was 35%.

The company is planning on filing a New Drug Application with the FDA, and sales could run into the hundreds of millions. Lexicon has partnered the drug overseas with a company called Ipsen. However, it retains rights in the U.S. and Japanese markets.

Recs

0
Member Avatar manirg (< 20) Submitted: 8/28/2015 10:19:46 PM : Outperform Start Price: $11.94 LXRX Score: -49.76

Fool Sean's pick & I like it too!!

Leaderboard

Find the members with the highest scoring picks in LXRX.

Score Leader

sglubis2

sglubis2 (95.95) Score: +195.45

The Score Leader is the player with the highest score across all their picks in LXRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
sglubis2 95.95 9/16/2009 Underperform 3M $19.60 -50.66% +144.47% +195.13 0 Comment
chuckyd5737 < 20 9/18/2006 Underperform 3M $26.39 -63.36% +107.67% +171.03 0 Comment
stockjock11 < 20 1/20/2010 Underperform NS $16.94 -42.92% +127.32% +170.24 0 Comment
radmtom < 20 1/20/2010 Underperform 1Y $16.73 -42.20% +127.34% +169.54 0 Comment
IceNineTX < 20 11/27/2006 Underperform 3M $27.02 -64.21% +95.44% +159.65 1 Comment
longtermgrowth09 < 20 12/17/2009 Underperform 5Y $12.60 -23.25% +133.16% +156.41 0 Comment
SLTiger < 20 1/3/2007 Underperform NS $25.41 -61.94% +92.62% +154.57 0 Comment
str8nuts < 20 1/19/2010 Underperform 3W $13.65 -29.16% +124.36% +153.52 0 Comment
Forestboy 99.61 1/22/2007 Underperform NS $23.10 -58.14% +91.52% +149.66 0 Comment
abedamri < 20 10/22/2009 Underperform 5Y $10.71 -9.71% +138.19% +147.90 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPoisedTo < 20 7/20/2012 Underperform 5Y $19.46 -50.31% +88.50% +138.81 0 Comment
TrackPoisedTo < 20 2/8/2012 Underperform 5Y $12.04 +65.70% +2.05% -63.64 7/19/2012 @ $19.95 0 Comment
TrackNeedham 91.65 5/27/2011 Outperform NS $10.64 -9.12% +93.56% -102.68 0 Comment
TrackWedbush 87.19 4/26/2011 Outperform NS $11.97 -19.21% +92.58% -111.79 0 Comment
TrackWayneRogers 58.93 1/7/2011 Outperform 3M $14.00 -30.93% +103.04% -133.97 0 Comment
TrackZacks < 20 10/21/2008 Outperform 3M $10.99 -18.47% +14.04% -32.51 7/13/2010 @ $8.96 1 Comment
TrackZacks < 20 5/1/2008 Outperform 3M $14.70 -32.38% -29.98% -2.40 10/20/2008 @ $9.94 1 Comment
TrackEveillard 94.72 12/31/2007 Outperform NS $21.21 -54.41% +84.01% -138.42 1 Comment
TrackPZK < 20 8/7/2007 Outperform NS $21.77 -48.87% -6.60% -42.28 4/17/2012 @ $11.13 0 Comment
TrackBofASec 93.75 5/15/2007 Outperform NS $23.66 -59.13% +81.10% -140.23 0 Comment
TrackPiperJaff 85.06 2/22/2007 Outperform NS $29.05 -62.41% -10.81% -51.60 3/7/2008 @ $10.92 0 Comment
TrackRBCCapMkts 88.53 1/30/2007 Outperform NS $25.97 0% +8.01% -8.01 10/31/2007 @ $25.97 0 Comment

Featured Broker Partners